ArQule, Inc. (NASDAQ:ARQL)

CAPS Rating: 3 out of 5

A clinical-stage biotechnology company, engaged in the research and development of cancer therapeutics. Its mission is to research, develop and commercialize targeted cancer drugs with reduced toxicities compared to conventional cancer chemotherapeutics.

Caps

This ticker is not currently Ratable.

Add Stock to CAPS Watchlist

All Players

165 Outperform
21 Underperform
 

All-Star Players

42 Outperform
6 Underperform
 

Wall Street

11 Outperform
0 Underperform
 

Top ARQL Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

MrOneHundred (32.43)
Submitted February 24, 2013

I'm having a hard time reconciling a decent reason not to risk this stock with real money. In my opinion, at $2/share the company is poised to repeat miraculous gains in a relatively near future. Only twice in the past eleven years has this stock… More

pajeth (< 20)
Submitted February 19, 2007

Carefully watching this stock, hoping for some positive news.

ARQL VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from players about ARQL.

Recs

0
Member Avatar zzlangerhans (99.76) Submitted: 10/14/2016 10:14:42 AM : Outperform Start Price: $1.50 ARQL Score: -33.08

I'm green-thumbing ArQule mainly out of nostalgia. This is one of the original stocks I began my biotech database wqith ten years ago and they've had their share of ups and downs. Even after all this time, it remains to be seen whether they end up like Synta or Exelixis. Right now the share price is a lot closer to Synta's (before they reverse-merged out of existence). ArQule seems to be in the process of reinventing themselves, highlighting early data for FGFR inhibitor ARQ087 in intrahepatic cholangiocarcinoma and AKT inhibitor ARQ092 for Proteus syndrome. Even preclinical BTK inhibitor ARQ531 gets higher billing over the ongoing phase III trials of tivantinib for hepatocellular carcinoma, which leads me to suspect the company has low expectations for the results expected by early 2017.

ArQule still trades well over cash despite a lack of any proven winner in their pipeline, which means it doesn't fit the profile for a real zzporte position for now. I don't expect a major decline in share price after the tivantinib trials fail, but I could be wrong as I was with Immunomedics and epratuzumab. If ArQule's cap does drop below cash at that point, it could provide a very interesting opportunity for entry.

Recs

0
Member Avatar chall77 (< 20) Submitted: 2/1/2014 6:40:50 PM : Outperform Start Price: $2.30 ARQL Score: -83.25

I understand they have a promising liver drug on the way that is supposed to be a strong performer for the company

Recs

2
Member Avatar MrOneHundred (32.43) Submitted: 2/24/2013 3:56:22 AM : Outperform Start Price: $2.41 ARQL Score: -108.28

I'm having a hard time reconciling a decent reason not to risk this stock with real money. In my opinion, at $2/share the company is poised to repeat miraculous gains in a relatively near future. Only twice in the past eleven years has this stock been this low. Its price has climbed up to as high as $10 in times past! With the company's current pipeline, a plausible economic crisis (something this sector can be relatively immune to and could therefore draw investors), and add in the fact that ArQule is presenting at the RBC Capital Markets Global Healthcare Conference coming this Tuesday... it seems likely that something positive, no matter how minute, will likely send this stock up quick. Dilution, or other bad things could happen, but I'm having a difficult time seeing it happen with this company. The fundamentals on this stock are shaky, though. This is not without risk.

Leaderboard

Find the members with the highest scoring picks in ARQL.

Score Leader

BearTrend

BearTrend (88.30) Score: +284.92

The Score Leader is the player with the highest score across all their picks in ARQL.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
BearTrend 88.30 1/23/2009 Underperform 5Y $3.94 -69.04% +200.47% +269.51 0 Comment
Monica109 85.60 4/2/2009 3/30/2014 Underperform 5Y $4.41 -72.34% +194.96% +267.30 0 Comment
anticitradeshort 29.91 4/20/2009 Underperform NS $4.37 -72.08% +186.48% +258.56 0 Comment
rockfishcc8 65.51 7/15/2009 Underperform 3M $6.02 -79.73% +162.27% +242.01 0 Comment
Hero4All 30.10 6/12/2009 Underperform 5Y $5.58 -78.14% +159.68% +237.81 0 Comment
stockjock11 < 20 3/31/2010 Underperform NS $6.94 -82.41% +107.08% +189.49 0 Comment
longtermgrowth09 < 20 8/3/2010 Underperform 5Y $4.32 -71.76% +115.62% +187.38 0 Comment
seanchile 91.20 4/1/2010 Underperform 3Y $5.79 -78.93% +106.69% +185.62 0 Comment
foolstracker < 20 4/7/2010 Underperform 5Y $6.31 -80.67% +104.15% +184.82 0 Comment
Rihanna 98.68 4/12/2010 Underperform 3M $6.20 -80.32% +102.41% +182.73 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackStifel 94.29 3/15/2012 Outperform NS $7.23 -83.13% +73.09% -156.21 0 Comment
TrackRBCCapMkts 89.79 1/31/2012 Outperform NS $7.58 -83.91% +83.71% -167.61 0 Comment
trackglobalhunte < 20 5/26/2011 Outperform NS $6.51 -81.26% +83.69% -164.95 0 Comment
TrackMehtaPartne < 20 4/5/2010 Outperform NS $5.88 -79.25% +105.10% -184.35 0 Comment
TrackUBS 93.16 10/14/2009 Outperform NS $4.35 -71.95% +125.84% -197.79 0 Comment
TrackUBS 93.16 7/16/2009 Underperform NS $5.38 -19.14% +15.38% +34.52 10/13/2009 @ $4.35 0 Comment
TrackOppenheimer 71.49 12/1/2008 Outperform NS $3.29 -62.92% +184.35% -247.27 0 Comment
TrackBofASec 95.81 9/3/2008 Outperform NS $3.44 -64.53% +95.65% -160.19 0 Comment
TrackUBS 93.16 1/29/2008 Outperform NS $5.18 -17.37% -38.52% +21.15 4/3/2009 @ $4.28 0 Comment
TrackBofASec 95.81 12/4/2007 Outperform NS $6.62 -29.31% -4.69% -24.61 1/9/2008 @ $4.68 0 Comment
TrackEveillard 95.65 9/30/2007 Outperform NS $7.13 -82.89% +66.54% -149.43 1 Comment
TrackLazardCapit 81.47 9/14/2007 Outperform NS $7.68 -84.11% +72.05% -156.16 0 Comment
TrackNeedham 90.98 6/1/2007 Outperform NS $9.37 -25.93% -13.76% -12.17 3/31/2011 @ $6.94 0 Comment
TrackCantorFitz 25.18 5/22/2007 Outperform NS $9.46 -87.10% +67.92% -155.02 0 Comment
TrackStanfordRes < 20 5/3/2007 Outperform NS $9.11 -19.10% -8.15% -10.95 4/17/2012 @ $7.37 0 Comment
TrackFortisBank < 20 4/30/2007 Outperform NS $9.28 -70.04% -28.25% -41.79 10/2/2008 @ $2.78 0 Comment
TrackLeerinkSwan 98.65 4/4/2007 Outperform NS $7.74 -84.24% +78.49% -162.73 0 Comment
TrackWRHambrecht < 20 3/8/2007 Outperform NS $6.52 +13.04% -2.17% +15.21 4/17/2012 @ $7.37 0 Comment

Featured Broker Partners